February 22nd 2022, 4:41pm
Although the data failed to identify a predictive biomarker in patients with advanced kidney cancer, an expert from Memorial Sloan Kettering Cancer Center in New York notes that the results indicate that no one should be excluded from receiving Lenvima plus Keytruda.
February 22nd 2022, 2:08pm
Tecentriq failed to meet the progression-free survival goal in a trial analyzing the immunotherapy agent in advanced squamous cell carcinoma of the penis.
February 21st 2022, 8:00pm
Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.
February 21st 2022, 4:00pm
Fotivda – a TKI drug that was approved last year – not only improved survival outcomes, but was also very tolerable in terms of side effects for patients with metastatic renal cell carcinoma.
February 23rd 2021, 2:00pm
Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.
February 18th 2021, 2:00pm
The study results, according to one expert, show that Cabometyx should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
February 15th 2021, 10:00pm
Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.
February 13th 2021, 10:00pm
The results of the phase 3 trial, according to one expert, support the use of Lenvima with Keytruda as a possible first-line treatment option for patients with advanced renal cell carcinoma.
February 13th 2021, 6:00pm
Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.
February 13th 2021, 4:00pm
For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team.
The Impact of the Oncology Nurse Navigator on the Lives of Patient and Caregiver
Checkmate: Beating Cancer at Its Own Game
The Value of Time in Cancer Care
Tecvayli Effective in BCMA-Pretreated R/R Multiple Myeloma